Results 1 to 10 of about 31,151 (261)

Special Issue “Virus-Like Particle Vaccines” [PDF]

Viruses, 2020
Virus-like particles (VLPs) have become a key tool for vaccine developers and manufacturers [...]
Monique Vogel, Martin F. Bachmann
doaj   +3 more sources

Virus-like Particle Vaccines and Platforms for Vaccine Development

Viruses, 2023
Virus-like particles (VLPs) have gained a lot of interest within the past two decades. The use of VLP-based vaccines to protect against three infectious agents—hepatitis B virus, human papillomavirus, and hepatitis E virus—has been approved; they are ...
Milad Kheirvari, Hong Liu, Ebenezer Tumban   +2 more
doaj   +3 more sources

Research Progress Towards Poliovirus Virus-like Particle Vaccines: A Review [PDF]

Vaccines
Poliovirus (PV), a historically significant enterovirus responsible for severe paralytic diseases, has seen its incidence dramatically reduced through widespread vaccination efforts, propelling global eradication initiatives.
Taoli Han, Jinbo Xiao, Shiyao Zhang, Tongyue Su, Yinuo Liu, Yong Zhang   +5 more
doaj   +2 more sources

Virus-like particle vaccines: immunology and formulation for clinical translation

Expert Review of Vaccines, 2018
Introduction: Virus-like particle (VLP) vaccines face significant challenges in their translation from laboratory models, to routine clinical administration. While some VLP vaccines thrive and are readily adopted into the vaccination schedule, others are
Braeden Donaldson, Zabeen Lateef, Greg F. Walker, Sarah L. Young, Vernon K. Ward   +4 more
doaj   +2 more sources

Influenza virus-like particle vaccines

Expert Review of Vaccines, 2009
Enveloped virus-like particle (VLP) vaccines containing influenza hemagglutinin (HA) and neuraminidase (NA) antigens are produced easily in insect or mammalian cells via the simultaneous expression of HA and NA along with a viral core protein, such as influenza matrix (M1) or a retroviral Gag protein.
exaly   +3 more sources

The 5th virus-like particle and nano-particle vaccines (VLPNPV) conference

Expert Review of Vaccines, 2019
Virus-like particles (VLPs) and nano-particles (NPs) are promising vaccine platforms that have led to the successful development of commercially available vaccines.
Paul Engeroff, Martin F. Bachmann
doaj   +4 more sources

Preclinical Development of a Novel Zika Virus-like Particle Vaccine in Combination with Tetravalent Dengue Virus-like Particle Vaccines

Vaccines
Declared as a Public Health Emergency in 2016 by the World Health Organization (WHO), the Zika virus (ZIKV) continues to cause outbreaks that are linked to increased neurological complications.
Dominik A. Rothen, Sudip Kumar Dutta, Pascal S. Krenger, Alessandro Pardini, Anne-Cathrine S. Vogt, Romano Josi, Ilva Lieknina, Albert D. M. E. Osterhaus, Mona O. Mohsen, Monique Vogel, Byron Martina, Kaspars Tars, Martin F. Bachmann   +12 more
doaj   +4 more sources

Norwalk virus-like particles as vaccines [PDF]

Expert Review of Vaccines, 2010
Noroviruses (NoV) cause the great majority of epidemic nonbacterial gastroenteritis in humans. Expression of the capsid protein in recombinant systems, including insect and plant cells, yields assembly of virus-like particles (VLPs) that mimic the antigenic structure of authentic virions, and are relatively acid- and heat-stable.
Melissa, Herbst-Kralovetz, Hugh S, Mason, Qiang, Chen   +2 more
openaire   +2 more sources

Versatile virus-like particle carrier for epitope based vaccines. [PDF]

PLoS ONE, 2010
BACKGROUND: Recombinant proteins and in particular single domains or peptides are often poorly immunogenic unless conjugated to a carrier protein. Virus-like-particles are a very efficient means to confer high immunogenicity to antigens.
Alain C Tissot, Regina Renhofa, Nicole Schmitz, Indulis Cielens, Edwin Meijerink, Velta Ose, Gary T Jennings, Philippe Saudan, Paul Pumpens, Martin F Bachmann   +9 more
doaj   +1 more source

RNA Phage VLP-Based Vaccine Platforms

Pharmaceuticals, 2021
Virus-like particles from a variety of RNA bacteriophages have turned out to be useful platforms for delivery of vaccine antigens in a highly immunogenic format.
David S. Peabody, Julianne Peabody, Steven B. Bradfute, Bryce Chackerian   +3 more
doaj   +1 more source